Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 401–500 of 1,010
Unveiling the neuroprotective potential of dietary polysaccharides: a systematic review
Guo, R., Pang, J., Zhao, J., Xiao, X., Li, J., Li, J., Wang, W., Zhou, S., Zhao, Y., Zhang, Z., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1299117 · Cited by 29
“Alzheimer’s disease (AD) is a common neurodegenerative disease worldwide and one of the most prevalent forms of dementia in the elderly (32).”
BackgroundInfluentialWu, H., Duan, Y., Jiang, L., Cao, X., Xie, Z., Quan, Y., Ren, M. X., Wu, S., Zhang, N., Yang, Z., et al. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c00674 · Cited by 29
Li, J., Ebrahimi, A., & Ali, A. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105169 · Cited by 31
“…19 forms ApoE4 lipoprotein, which is inefficient at removing amyloid beta (A β ) plaques from the brain’s cortical regions, thereby escalating AD risk, and presenilin 1 and 2 genes, responsible for the catalytic subunit of γ -secretase transcription, which have been reviewed previously [8–10].”
ANALYZE-AD: A comparative analysis of novel AI approaches for early Alzheimer’s detection
Chakraborty, M., Naoal, N., Momen, S., & Mohammed, N. (2024) · Array · doi:10.1016/j.array.2024.100352 · Cited by 28
Zhu, L., Zhou, T., Wu, L., Zhu, X., Chen, L., Zhang, M., Zhou, J., & Wang, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-09563-1 · Cited by 33
Tashima, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020411 · Cited by 27
“Other existing AD drugs, such as four cholinesterase inhibitors (tacrine, donepezil, rivastigmine, and galantamine) and an N-methyl-D-aspartate (NMDA) receptor antagonist (memantine) (Figure 1) [3], have been found to transiently slow down the progression of symptoms; however, they do not lead to definitive therapy.”
BackgroundSleep–Wake Disorders in Alzheimer’s Disease: A Review
Sun, Y.-Y., Wang, Z., Zhou, H.-Y., & Huang, H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00097 · Cited by 30
Iqbal, D., Rizvi, S. M. D., Rehman, M. T., Khan, M. S., Dukhyil, A. B., Alajmi, M. F., Alshehri, B., Banawas, S., Zia, Q., Alsaweed, M., et al. (2022) · Entropy · doi:10.3390/e24050593 · Cited by 27
Sun, L., Liu, T., Liu, J., Gao, C., & Zhang, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.929781 · Cited by 31
“As for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), the progressive death of neurons commonly induces irreversible neuronal cognitive deficits, motor disability, and complex behavioral dysregulation (3).”
Backgroundde Torre, M. P., Cavero, R. Y., & Calvo, M. I. (2022) · Molecules · doi:10.3390/molecules27207100 · Cited by 35
“Risk factors to develop AD include both genetic (gene ApoE4) and environmental factors (age, depression, metabolic syndrome: HTA, diabetes and hyperlipidaemia) [1].”
BackgroundChen, B., Wu, J., Hu, S. H., Liu, Q., Yang, H., & You, Y. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03844-1 · Cited by 31
Abdallah, I. M., Al-Shami, K. M., Alkhalifa, A. E., Al-Ghraiybah, N. F., Guillaume, C., & Kaddoumi, A. (2023) · Molecules · doi:10.3390/molecules28031249 · Cited by 28
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the most common type of dementia [1].”
BackgroundJett, S., Boneu, C., Zarate, C., Carlton, C., Kodancha, V., Nerattini, M., Battista, M., Pahlajani, S. S., Williams, S., Dyke, J. P., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1183228 · Cited by 32
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 30
“Since AD and PD are the most common neurodegenerative disorders (4% of individuals over 65 and 1% of people o ver the age of 60, respectively), the review will focus mainly on these diseases [7, 8].”
BackgroundLiang, H., Ma, Z., Zhong, W., Liu, J., Sugimoto, K., & Chen, H. (2024) · Phytotherapy Research · doi:10.1002/ptr.8156 · Cited by 29
“…the disease, and existing medications for other neurodegenerative disorders, including amyotrophic lateral sclerosis and Alzheimer's disease, can only ameliorate clinical symptoms without reversing neuronal loss (Amado & Davidson, 2021; Breijyeh & Karaman, 2020; Fox et al., 2018; Sun & Roy, 2021).”
BackgroundKassab, A. E., Gedawy, E. M., & Sayed, A. S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131018 · Cited by 31
Zhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26
(2024) · doi:10.3390/ijms25126698 · Cited by 26
Poor Oral Health Linked with Higher Risk of Alzheimer’s Disease
Kulkarni, M. S., Miller, B. C., Mahani, M., Mhaskar, R. S., Tsalatsanis, A., Jain, S., & Yadav, H. (2023) · Brain Sciences · doi:10.3390/brainsci13111555 · Cited by 29
“AD is a multifactorial disease with multiple risk factors, including age, gender, genetics, comorbidities, such as metabolic and cardiovascular diseases, and environmental conditions [2].”
BackgroundMechanisms by which microbiome-derived metabolites exert their impacts on neurodegeneration
Kern, L., Mastandrea, I., Melekhova, A., & Elinav, E. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.08.014 · Cited by 29
Improving Alzheimer’s Detection With Deep Learning and Image Processing Techniques
Alwakid, G. N., Tahir, S., Humayun, M., & Gouda, W. (2024) · IEEE Access · doi:10.1109/access.2024.3481238 · Cited by 34
“Alzheimer’s disease (AD) is a progressive neurological disorder marked by the gradual degeneration of brain cells, leading to impairments in memory, cognition, behavior, and daily functioning [1], [2].”
BackgroundMolecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review
Ali, N., Sayeed, U., Shahid, S. M. A., Akhtar, S., & Khan, M. K. A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10463-w · Cited by 30
Kariyawasam, K. P., Somaratne, G., Dillimuni, S. D., & Walallawita, U. S. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70788 · Cited by 33
“Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning (Breijyeh and Karaman 2020).”
Neuroinflammation and Alzheimer's disease: Unravelling the molecular mechanisms
Kakkar, A., Singh, H., Singh, B. K., Kumar, A., Mishra, A. K., & Chopra, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374353 · Cited by 29
Ibi, D., Kondo, S., Ohmi, A., Kojima, Y., Nakasai, G., Takaba, R., & Hiramatsu, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03622-z · Cited by 27
Mirza, F. J., & Zahid, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1058358 · Cited by 30
“Cholinesterase enzyme inhibitors and N-methyl d-aspartate (NMDA) antagonists function mainly by treating the symptoms of AD and do not possess preventive or curative effects (Breijyeh and Karaman, 2020).”
BackgroundThioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease
Tonelli, M., Catto, M., Sabaté, R., Francesconi, V., Laurini, E., Pricl, S., Pisani, L., Miniero, D. V., Liuzzi, G. M., Gatta, E., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115169 · Cited by 26
Doença de Alzheimer no Brasil: uma análise epidemiológica entre 2013 e 2022
Araújo, S. R. M., Cunha, E. R., Marques, I. L., Paixão, S. A., Dias, A. D. F. G., de Sousa, P. M., Soares, N. D. K. P., Sousa, M. O., Lobato, R. M., & de Souza, M. T. P. (2023) · Research Society and Development · doi:10.33448/rsd-v12i2.40345 · Cited by 37
Bhanukiran, K., Singh, R., Gajendra, T. A., Ramakrishna, K., Singh, S. K., Krishnamurthy, S., Kumar, A., & Hemalatha, S. (2023) · Phytomedicine Plus · doi:10.1016/j.phyplu.2023.100439 · Cited by 29
Gene Interactions in Human Disease Studies—Evidence Is Mounting
Singhal, P., Verma, S. S., & Ritchie, M. D. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-102022-120818 · Cited by 27
Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
Eddin, A. N., Hamsho, K., Adi, G., Al-Rimawi, M., Alfuwais, M., Rab, S. A., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1210191 · Cited by 27
“These three events all eventually contribute to the synaptic dysfunction and neuronal loss primarily seen in the medial temporal lobe, frontal cortex, and hippocampus of AD patients (Shimanoe et al., 2019; Breijyeh and Karaman, 2020).”
BackgroundAmeliorative effects of probiotics in AlCl3-induced mouse model of Alzheimer’s disease
Hamid, M., & Zahid, S. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12686-y · Cited by 26
Zhuang, X., Zhang, G., Bao, M., Jiang, G., Wang, H., Li, S., Wang, Z., & Sun, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147501 · Cited by 28
Wahlberg, K. E., Winblad, B. G., Cole, A., Herring, W. L., Ramsberg, J., Torontali, I., Visser, P. J., Wimo, A. B., Wollaert, L., & Jönsson, L. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13759 · Cited by 28
“The symptoms of AD increase gradually over the course of the disease, from memory loss in the prodromal stage of AD dementia to significant functional and cognitive impairment with potentially lethal consequences in the severe clinical phase [5].”
BackgroundHistogram-based features track Alzheimer's progression in brain MRI
Pasnoori, N., Flores-Garcia, T., & Barkana, B. D. (2024) · Scientific Reports · doi:10.1038/s41598-023-50631-1 · Cited by 26
Iranpanah, A., Fakhri, S., Bahrami, G., Majnooni, M. B., Gravandi, M. M., Taghavi, S., Badrbani, M. A., Amirian, R., & Farzaei, M. H. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117708 · Cited by 26
From the Mind to the Spine: The Intersecting World of Alzheimer’s and Osteoporosis
Margetts, T. J., Wang, H. S., Karnik, S. J., Plotkin, L. I., Movilă, A., Oblak, A. L., Fehrenbacher, J. C., & Kacena, M. A. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00848-w · Cited by 33
“Lifestyle factors such as diet, exercise, and cognitive training also play a role in maintaining cognitive function and may potentially help in preventing AD [24].”
BackgroundInfluentialPaidlewar, M., Kumari, S., Dhapola, R., Sharma, P., & HariKrishnaReddy, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112940 · Cited by 28
PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease
Wang, Q., Wang, Y., Li, S., & Shi, J. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01334-2 · Cited by 30
“Alzheimer’s disease (AD), as a neurodegenerative disease, causes a progressively cognitive decline [1, 2].”
BackgroundDoroszkiewicz, J., Winkel, I., & Mroczko, B. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1579511 · Cited by 30
“Classical neurodegenerative diseases include Parkinson’s disease (PD) and Alzheimer’s disease (AD) (Breijyeh and Karaman, 2020; Marogianni et al., 2020).”
Extracellular vesicles in age-related diseases: disease pathogenesis, intervention, and biomarker
Putri, P. H. L., Alamudi, S. H., Dong, X., & Fu, Y. L. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04374-7 · Cited by 28
“The pathogenic role of EVs in AD Alzheimer’s disease occurs as a result of the accumulation of amyloid-beta (Aβ) peptides in the medial temporal lobe and neocortical structures of the brain [66].”
Rawish, E., & Langer, H. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126585 · Cited by 30
“The global prevalence is estimated to be as high as 50 million and is predicted to reach 152 million by 2050 [47].”
BackgroundPavan, M., Menin, S., Bassani, D., Sturlese, M., & Moro, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909499 · Cited by 28
Rodà, F., Picciolini, S., Mangolini, V., Gualerzi, A., Seneci, P., Renda, A., Sesana, S., Re, F., & Bedoni, M. (2023) · Nanomaterials · doi:10.3390/nano13040699 · Cited by 30
“Instead, about 50 million people are affected by AD, and the number is increasing rapidly due to the population aging and living longer [14].”
BackgroundA Review of the Benefits 3D Printing Brings to Patients with Neurological Diseases
Gander, C., Shi, K., Nokhodchi, A., & Lam, M. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030892 · Cited by 29
“This debilitating disease causes memory loss and changes in personality, which greatly burdens patients, their families, and the economy with an estimated USD 1 trillion annually [3].”
BackgroundA systematic review of the association between dementia risk factors and cerebrovascular reactivity
Wang, C., Reid, G., Mackay, C. E., Hayes, G., Bulte, D. P., & Suri, S. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105140 · Cited by 28
“Dementia risk factors were selected based on the literature (Breijyeh and Karaman, 2020; Livingston et al., 2020; Serrano-Pozo et al., 2021).”
MethodALZHEIMER’S DISEASE AND ITS RELATIONSHIP WITH THE MICROBIOTA-GUT-BRAIN AXIS
Faulin, T. D. E. S., & Estadella, D. (2023) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202301000-17 · Cited by 30
“In the mild phase, there is loss of concentration and memory, disorientation of place and time, mood swings and depression (17) , and even memory distortions may occur (19) .”
BackgroundRecent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer’s Disease
Su, M., Nizamutdinov, D., Liu, H., & Huang, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119272 · Cited by 28
“These harmful accumulative lesions lead to neural and synaptic degeneration [1,7].”
BackgroundSandison, H., Callan, N. G. L., Rao, R. V., Phipps, J. C., & Bradley, R. D. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230004 · Cited by 27
Schmidt-Morgenroth, I., Michaud, P., Gasparini, F., & Avraméas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310523 · Cited by 27
The elusive role of herpesviruses in Alzheimer’s disease: current evidence and future directions
Piotrowski, S. L., Tucker, A., & Jacobson, S. (2023) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2023-0011 · Cited by 24
“decline in AD is poorly understood [2, 5, 7].”
BackgroundInfluentialCausal relationship between gut microflora and dementia: a Mendelian randomization study
Fu, J., Qin, Y., Xiao, L., & Dai, X. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1306048 · Cited by 27
“Since there is no method of preventing, reversing, or eradicating Alzheimer’s disease, medications licensed for the therapy of Alzheimer’s disease have only been able to slow progression to improve symptoms (Breijyeh and Karaman, 2020).”
MethodNicola, L., Loo, S. J. Q., Lyon, G., Turknett, J., & Wood, T. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102356 · Cited by 25
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 28
Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
Zota, I., Chanoumidou, K., Gravanis, A., & Charalampopoulos, I. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1422130 · Cited by 25
Sadeghi, M., Seyedebrahimi, S., Ghanadian, M., & Miroliaei, M. (2024) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2024.100146 · Cited by 24
“Alzheimer ’ s disease (AD) is a neurodegenerative disorder characterized by a gradual and progressive decline in memory and cognitive functions (Breijyeh and Karaman, 2020).”
BackgroundNeolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic review
Li, N., Liang, Y., Zhang, L., Xu, C., & Wang, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102398 · Cited by 27
Lavanya, M., Namasivayam, S. K. R., Priyanka, S. G. S., & Abiraamavalli, T. (2024) · 3 Biotech · doi:10.1007/s13205-024-04158-5 · Cited by 25
PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier
Szecskó, A., Mészáros, M., Simões, B. T., Cavaco, M. C., Chaparro, C. I. P., Porkoláb, G., Castanho, M. A. R. B., Deli, M. A., Neves, V., & Veszelka, S. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00641-0 · Cited by 30
“They are designed to bind to specific targets in the brain, such as pathogenic proteins or molecules, minimizing off-target effects, promoting clearance mechanisms, or modulating neuroinflammation [15, 16].”
Shaikh, M. R., Jeyabose, A., & Arjunan, R. V. (2025) · BioMedical Engineering OnLine · doi:10.1186/s12938-025-01482-6 · Cited by 30
“Figure 4 compares healthy hippocampal anatomy with that seen in AD, underscoring the importance of this region’s early atrophy [8].”
Mechanistic research and therapeutic prospects of alternative splicing in neurodegenerative diseases
Ran, X., Wang, M., Huang, J., Kuang, N., Tian, P., Wu, J., Feng, F., Luo, Y., & Huang, N. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103133 · Cited by 26
Huo, S., Cheng, L., Li, S., & Xu, F. (2022) · Brain and Behavior · doi:10.1002/brb3.2488 · Cited by 26
Lü, J., Liu, L., Chen, J., Zhi, J., Li, J., Li, L., & Jiang, Z. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221091424 · Cited by 25
“Alzheimer’s disease (AD) is a burdensome dysfunction that is conducive to degeneration of brain and dementia.(1) In the clinic, AD is often viewed as progressive amnesia, aphasia, apraxia, and visual space disorder.”
BackgroundA Diagnostic Model for Alzheimer’s Disease Based on Blood Levels of Autophagy-Related Genes
Qin, Q., Gu, Z., Li, F., Pan, Y., Zhang, T., Yang, F., & Zhang, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.881890 · Cited by 26
Zhang, X., Lin, L., Li, H., Xia, W., Liu, Q., Zhou, X., Lin, D., & Fu, X. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.158 · Cited by 27
Chopra, G., Shabir, S., Yousuf, S., Kauts, S., Bhat, S. A., Mir, A. H., & Singh, M. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03042-8 · Cited by 25
Lin, W., Lin, Y., Yang, F., Chung, C., Hu, J., Tsao, C., Weng, Z., Ko, C.-A., & Chien, W. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.05.014 · Cited by 27
Shi, W., Zhang, G.-W., Liao, Y.-J., Fei, X.-Y., Gong, D.-M., & Hu, X. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.103174 · Cited by 20
Chemical Synthesis of Microtubule-Associated Protein Tau
Powell, W. C., Jing, R., & Walczak, M. A. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07338 · Cited by 24
Mind Gaps and Bone Snaps: Exploring the Connection Between Alzheimer’s Disease and Osteoporosis
Wang, H. S., Karnik, S. J., Margetts, T. J., Plotkin, L. I., Movilă, A., Fehrenbacher, J. C., Kacena, M. A., & Oblak, A. L. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00851-1 · Cited by 25
Pimentel, C., Le, C., Tuttobene, M. R., Subils, T., Martinez, J., Sieira, R., Papp‐Wallace, K. M., Keppetipola, N., Bonomo, R. A., Actis, L. A., et al. (2021) · Pathogens · doi:10.3390/pathogens10040471 · Cited by 24
Nadeem, M. S., Khan, J. A., & Rashid, U. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.102 · Cited by 25
Early prediction of dementia using fMRI data with a graph convolutional network approach
Han, S., Sun, Z., Zhao, K., Duan, F., Caiafa, C. F., Zhang, Y., & Solé-Casals, J. (2024) · Journal of Neural Engineering · doi:10.1088/1741-2552/ad1e22 · Cited by 23
“Alzheimer’s disease (AD) is a neurodegenerative dementia that progressively disrupts neurocognitive functions and poses a significant global health threat [1, 2].”
Boyton, I., Valenzuela, S. M., Collins‐Praino, L. E., & Care, A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.004 · Cited by 23
Zhang, T.-C., Lin, Y.-C., Sun, N., Liu, S., Hu, W.-Z., Zhao, Y. H., Dong, X.-H., & He, X.-P. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105705 · Cited by 24
Sheikh, M., & Ammar, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1398952 · Cited by 25
“The most prevalent form of dementia is Alzheimer’s disease (AD; Weller and Budson, 2018; Breijyeh and Karaman, 2020) responsible for about 70% of dementia cases (Aarsland, 2020; WHO, 2023), followed by vascular dementia (VaD; Hu et al., 2022; Morris et al., 2022) constituting about 20% (Aarsland,…”
BackgroundThe role of the FKBP51–Hsp90 complex in Alzheimer’s disease: An emerging new drug target
Jeanne, X., Török, Z., Vígh, L., & Prodromou, C. (2024) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2024.11.006 · Cited by 24
“71 Although approximately 14% of patients with mild to moderate AD either lack or show very sparse Aβ deposits.”
AlHayani, D. A., Kubaev, A., Uthirapathy, S., Mandaliya, V. B., Ballal, S., Kalia, R., Arya, R., Gabble, B. C., Alasheqi, M. Q., & KADHIM, A. J. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02324-9 · Cited by 23
“…mainly marked by the extracellular deposition of Aβ, forming senile plaques, and intracellular accumulation of hyper-phosphorylated tau, creating neurofibrillary tangles (NFTs), which disrupt microtubule stability and intracellular transport (Breijyeh and Karaman 2020; Singh et al. 2024).”
Meng, X., Du, H., Li, D., Guo, Y., Luo, P., Pan, L., Kan, R., Yu, P., Xiang, Y., Mao, B., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70089 · Cited by 26
Misregulation of Wnt Signaling Pathways at the Plasma Membrane in Brain and Metabolic Diseases
Karabicici, M., Azbazdar, Y., İşcan, E., & Özhan, G. (2021) · Membranes · doi:10.3390/membranes11110844 · Cited by 25
“The extra- and intracellular accumulation of amyloidbeta (Aβ) plaques and hyperphosphorylated Tau protein correlate strongly with cognitive impairment [60,62].”
BackgroundYoshida, N., Kato, Y., Takatsu, H., & Fukui, K. (2022) · Biomedicines · doi:10.3390/biomedicines10020281 · Cited by 23
“The most important symptom of AD is dementia via dysfunction of cholinergic neurons [2]; in particular, neuronal cell death occurs frequently in the hippocampal region [3].”
BackgroundDibacto, R. E. K., Ambamba, B. D. A., Ella, F. A., Nyangono, C. F. B., Nanhah, J. V. K., Fonkoua, M., Minka, R. S., & Ngondi, J. L. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09896 · Cited by 23
“And it competes with this cation for small ligands such as phosphates [56].”
BackgroundAnadozie, S. O., Effiom, D. O., Adewale, O. B., Jude, J., Zosela, I., Akawa, O. B., Olayinka, J. N., & Roux, S. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104604 · Cited by 27
Job, N., Thimmakondu, V. S., & Thirumoorthy, K. (2023) · Molecules · doi:10.3390/molecules28031388 · Cited by 23
“Several theories have been proposed to explain the root cause of AD, whilst the exact mechanism is still under debate [3,4].”
BackgroundZheng, R., Shi, S., Zhang, Q., Yuan, S., Guo, T., Guo, J., & Jiang, P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1140945 · Cited by 26
Transnasal-brain delivery of nanomedicines for neurodegenerative diseases
Zhang, X., Wang, M., Liu, Z., Wang, Y., Chen, L., Guo, J., Zhang, W., Zhang, Y., Yu, C., Bie, T., et al. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1247162 · Cited by 26
Zilinskaite, N., Shukla, R. P., & Baradokė, A. (2023) · ACS Measurement Science Au · doi:10.1021/acsmeasuresciau.3c00028 · Cited by 26
Munteanu, C., Iordan, D. A., Hoteteu, M., Popescu, C., POSTOIU, R. L., Onu, I., & Onose, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015481 · Cited by 24
Pollard, C. A., Aston, K. I., Emery, B. R., Hill, J. T., & Jenkins, T. G. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1272960 · Cited by 23
“Compounding the issue, the disease's gradual progression involves years of elevated neuronal cell death before visible symptoms emerge, with approximately 60 percent of neurons already lost by the time symptoms become apparent (1).”
BackgroundLipids, Gut Microbiota, and the Complex Relationship with Alzheimer’s Disease: A Narrative Review
Simão, D. O., Vieira, V. S., Tosatti, J. A. G., & Gomes, K. B. (2023) · Nutrients · doi:10.3390/nu15214661 · Cited by 22
“Other potential modifiable risk factors for AD are diet, physical inactivity, inadequate sleep, stress, inflammation, smoking, alcohol consumption, and an imbalance of the gastrointestinal microbiome (GM) [5,13,14].”
BackgroundHambali, A., Jusril, N. A., Hashim, N. F. M., Manan, N. A., Adam, S. K., Mehat, M. Z., Adenan, M. I., Stanslas, J., & Hamid, H. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230875 · Cited by 25
“This number is anticipated to double every five years and reach 152 million by 2050 [1].”
Gunawan, C., Fleming, C. L., Irga, P. J., Wong, R. J., Amal, R., Torpy, F. R., Golzan, M., & McGrath, K. C. Y. (2024) · Environment International · doi:10.1016/j.envint.2024.108512 · Cited by 26
Kowalska, A., Adamska, E., & Grobelna, B. (2024) · ChemMedChem · doi:10.1002/cmdc.202300672 · Cited by 25
Yusoff, A. A. M., & Khair, S. Z. N. M. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0080 · Cited by 31
The Importance of Gut Microbiota on Choline Metabolism in Neurodegenerative Diseases
Eslami, M., Alibabaei, F., Babaeizad, A., Banihashemian, S. Z., Mazandarani, M., Hoseini, A., Ramezankhah, M., Oksenych, V., & Yousefi, B. (2024) · Biomolecules · doi:10.3390/biom14111345 · Cited by 24
Early detection of Alzheimer’s disease in structural and functional MRI
Maity, R., Sankari, V. M. R., Umapathy, S., Velu, S. R., Alahmadi, T. J., Alhababi, Z. A., & Alkahtani, H. K. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1520878 · Cited by 23
“The second group assesses neuronal damage by detecting cerebrospinal fluid tau protein, metabolic activity with FDG, and shrinkage in MRI images (9–11).”
Cutipa-Díaz, Y. M., Lupaca, C. H., Sandoval, E. M. L., Huanca, D. Y. M., Esquiche, W. M. S., Rubira-Otárola, D. G., Gutiérrez-Cueva, R. N., & Sacari, E. J. S. (2024) · Water · doi:10.3390/w16172386 · Cited by 24
Jia, S., Guan, H., Zhang, S., & Li, Q. (2024) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v52i5.1680 · Cited by 23
“However, their effectiveness varies from person to person and fails to effectively stop or substantially delay the progression of the disease, often accompanied by low response rates and adverse reactions [3,4].”
BackgroundReho, P., Kalia, V., Jackson, G. L., Wang, F., Eiten, E., Brennan, K. J. M., Brickman, A. M., Mayeux, R. P., Miller, G. W., Vardarajan, B. N., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70050 · Cited by 25
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.